Neoadjuvant Chemotherapy Rather than Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer with High Tumor Burden

Koca D., ÖZTOP İ., Yilmaz U.

HEPATO-GASTROENTEROLOGY, cilt.59, sa.119, ss.2151-2154, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 59 Sayı: 119
  • Basım Tarihi: 2012
  • Doi Numarası: 10.5754/hge12006
  • Dergi Adı: HEPATO-GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2151-2154
  • Anahtar Kelimeler: Locally advanced rectal cancer, High tumor burden, Neoadjuvant chemotherapy, Neoadjuvant chemoradiotherapy, METASTATIC COLORECTAL-CANCER, POSTOPERATIVE ADJUVANT CHEMOTHERAPY, PREOPERATIVE RADIOTHERAPY, MESORECTAL EXCISION, RADIATION-THERAPY, PLUS IRINOTECAN, PHASE-II, FLUOROURACIL, CARCINOMA, SURVIVAL
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background/Aims: We investigated the characteristics of locally advanced rectal cancer (LARC) patients who had received neoadjuvant chemoradiotherapy (NCRT), and who developed early metastasis during the perioperative period. Methodology: LARC who were treated and followed-up were included in this study. Patients' files were reviewed retrospectively and the data on patients were recorded. Results: Totally, 182 stage II and III rectal cancer patients who received NCRT were retrospectively evaluated. Seventeen (9.3%) patients were metastatic during the perioperative period. Of them, metastases developed pre-operatively in 3 (17.6%) patients after NCRT, while 14 (82.4%) developed metastases postoperatively before adjuvant chemotherapy (CT). Twelve (70.6%) patients had clinical stage T4N+ disease. The median time interval between pathological diagnosis and metastasis development was 4 (3-5) months. The median survival was 24 months. Conclusions: More effective treatment is warranted in patients with LARC with a high tumor burden.